Daniel W. Kneller

Daniel W. Kneller

Auto-generated profile, based on publicly available information

Daniel W. Kneller

New England Biolabs, Inc

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DKDaniel W. Kneller
Daniel W. Kneller
GPGwyndalyn Phillips
Gwyndalyn Phillips
HOHugh M. O’nEill
Hugh M. O’nEill
RJRobert Jedrzejczak
Robert Jedrzejczak
LSLucy Stols
Lucy Stols
AKAndrey Kovalevsky
Andrey Kovalevsky
The COVID-19 disease caused by the SARS-CoV-2 coronavirus has become a pandemic health crisis. An attractive target for antiviral inhibitors is the main protease 3CL Mpro due to its essential role in processing the polyproteins translated from viral RNA. Here we report the room temperature X-ray structure of unliganded SARS-CoV-2 3CL Mpro, revealing the ligand-free structure of the active site and the conformation of the catalytic site cavity at near-physiological temperature. Comparison with previously reported low-temperature ligand-free and inhibitor-bound structures suggest that the room temperature structure may provide more relevant information at physiological temperatures for aiding in molecular docking studies.

18 November 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
ACAustin Clyde
Austin Clyde
SGStephanie Galanie
Stephanie Galanie
DKDaniel W. Kneller
Daniel W. Kneller
HMHeng Ma
Heng Ma
YBYadu Babuji
Yadu Babuji
RSRick L. Stevens
Rick L. Stevens
Despite the recent availability of vaccines against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the search for inhibitory therapeutic agents has assumed importance especially in the context of emerging new viral variants. In this paper, we describe the discovery of a novel noncovalent small-molecule inhibitor, MCULE-5948770040, that binds to and inhibits the SARS-Cov-2 main protease (Mpro) by employing a scalable high-throughput virtual screening (HTVS) framework and a targeted compound library of over 6.5 million molecules that could be readily ordered and purchased. Our HTVS framework leverages the U.S. supercomputing infrastructure achieving nearly 91% resource utilization and nearly 126 million docking calculations per hour. Downstream biochemical assays validate this Mpro inhibitor with an inhibition constant (Ki) of 2.9 μM (95% CI 2.2, 4.0). Furthermore, using room-temperature X-ray crystallography, we show that MCULE-5948770040 binds to a cleft in the primary binding site of Mpro forming stable hydrogen bond and hydrophobic interactions. We then used multiple μs-time scale molecular dynamics (MD) simulations and machine learning (ML) techniques to elucidate how the bound ligand alters the conformational states accessed by Mpro, involving motions both proximal and distal to the binding site. Together, our results demonstrate how MCULE-5948770040 inhibits Mpro and offers a springboard for further therapeutic design.

1 December 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DKDaniel W. Kneller
Daniel W. Kneller
GPGwyndalyn Phillips
Gwyndalyn Phillips
KWKevin L. Weiss
Kevin L. Weiss
SPSwati Pant
Swati Pant
QZQiu Zhang
Qiu Zhang
AKAndrey Kovalevsky
Andrey Kovalevsky
The main protease (3CL Mpro) from SARS–CoV-2, the etiological agent of COVID-19, is an essential enzyme for viral replication. 3CL Mpro possesses an unusual catalytic dyad composed of Cys145 and His41 residues. A critical question in the field has been what the protonation states of the ionizable residues in the substrate-binding active-site cavity are; resolving this point would help understand the catalytic details of the enzyme and inform rational drug development against this pernicious virus. Here, we present the room-temperature neutron structure of 3CL Mpro, which allowed direct determination of hydrogen atom positions and, hence, protonation states in the protease. We observe that the catalytic site natively adopts a zwitterionic reactive form in which Cys145 is in the negatively charged thiolate state and His41 is doubly protonated and positively charged, instead of the neutral unreactive state usually envisaged. The neutron structure also identified the protonation states, and thus electrical charges, of all other amino acid residues and revealed intricate hydrogen-bonding networks in the active-site cavity and at the dimer interface. The fine atomic details present in this structure were made possible by the unique scattering properties of the neutron, which is an ideal probe for locating hydrogen positions and experimentally determining protonation states at near-physiological temperature. Our observations provide critical information for structure-assisted and computational drug design, allowing precise tailoring of inhibitors to the enzyme's electrostatic environment.

1 December 2020 in Structure
Verified
Journal Article
Closed access
DKDaniel W. Kneller
Daniel W. Kneller
SGStephanie Galanie
Stephanie Galanie
GPGwyndalyn Phillips
Gwyndalyn Phillips
HOHugh M. O'NEill
Hugh M. O'NEill
LCLeighton Coates
Leighton Coates
AKAndrey Kovalevsky
Andrey Kovalevsky

21 September 2020 in IUCrJ
Verified
Journal Article
Open access
PDF file
DKDaniel W. Kneller
Daniel W. Kneller
GPGwyndalyn Phillips
Gwyndalyn Phillips
HOHugh M. O'Neill
Hugh M. O'Neill
KTKemin Tan
Kemin Tan
AJAndrzej Joachimiak
Andrzej Joachimiak
AKAndrey Kovalevsky
Andrey Kovalevsky
The emergence of the novel coronavirus SARS-CoV-2 has resulted in a worldwide pandemic not seen in generations. Creating treatments and vaccines to battle COVID-19, the disease caused by the virus, is of paramount importance in order to stop its spread and save lives. The viral main protease, 3CL Mpro, is indispensable for the replication of SARS-CoV-2 and is therefore an important target for the design of specific protease inhibitors. Detailed knowledge of the structure and function of 3CL Mpro is crucial to guide structure-aided and computational drug-design efforts. Here, the oxidation and reactivity of the cysteine residues of the protease are reported using room-temperature X-ray crystallography, revealing that the catalytic Cys145 can be trapped in the peroxysulfenic acid oxidation state at physiological pH, while the other surface cysteines remain reduced. Only Cys145 and Cys156 react with the alkylating agent N-ethylmaleimide. It is suggested that the zwitterionic Cys145–His45 catalytic dyad is the reactive species that initiates catalysis, rather than Cys145-to-His41 proton transfer via the general acid–base mechanism upon substrate binding. The structures also provide insight into the design of improved 3CL Mpro inhibitors.

11 June 2015 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
IWIrene Weber
Irene Weber
DKDaniel W Kneller
Daniel W Kneller
AWAndres Wong-Sam
Andres Wong-Sam
The virally encoded protease is an important drug target for AIDS therapy. Despite the potency of the current drugs, infections with resistant viral strains limit the long-term effectiveness of therapy. Highly resistant variants of HIV protease from clinical isolates have different combinations of about 20 mutations and several orders of magnitude worse binding affinity for clinical inhibitors. Strategies are being explored to inhibit these highly resistant mutants. The existing inhibitors can be modified by introducing groups with the potential to form new interactions with conserved protease residues, and the flexible flaps. Alternative strategies are discussed, including designing inhibitors to bind to the open conformation of the protease dimer, and inhibition of the protease-catalyzed processing of the Gag-Pol precursor.